a) Objectives: This study analyses the characteristics and prevalence of psychotic disorders in patients with substance use, that needed medical and psychiatric care in a Dual Pathology Department during a 3 years period. b) Background and aims: The strong comorbidity between substance use and psychotic disorders has been deeply studied in recent literature. The aim of this study is to analyse the characteristics of the psychotic episode (primary or drug-induced), the predominant substance of use and the age of onset of consumption, as well as some sociodemographic characteristics in these patients. c) Materials and methods After a bibliographic review of recent literature, we realize a descriptive study of psychotic disorders and substance use from a total of 531 hospitalized patients during a 3 years period, using SPSS for Windows 20.0 database for statistic results. d) Results: In this study we can observe a predominant percentage of males with an average age of 36 years old, around 50% psychotic disorders out of total number of patients with a predominant type of primary psychosis and a high prevalence of cocaine (18% of total patients), alcohol (16%) and cannabis (8%) use and also an early age of onset of problematic consumption (15 years old for alcohol, 16 years old for cannabis and 21 years old for cocaine). e) Conclusions: The result of this study approach the current literature data about psychotic disorders and substance use and underlines the importance of a correct and early diagnosis in patients with a serious mental illness.
IntroductionClozapine is the most effective antipsychotic for treatment resistant schizophrenia but adverse reactions to clozapine include neutropenia. Patients with COVID-19 infection frequently experience lymphopenia, but not neutropenia.The impact of clozapine treatment in the presence of COVID-19 is unknownObjectivesShow 2 cases of neutropenia in patients treated with long-term clozapine during COVID-19 infection.MethodsSubjects: 48 admitted patients to a long-stay psychiatric unit. COVID-19 infection confirmed by positive nasopharyngeal swab for viral ribonucleic acid of SARS-CoV-2. Hematological controls between March and April 2020.Results16 patients (33%) treated with clozapine.18 patients (37’5%) had COVID-19 infection, of which 5 (10’4%) were treated with clozapine; 2 presented neutropenia. 1- 56-year-old woman diagnosed with schizophrenia on clozapine since 2009. Begins to have a dry cough and fever with positive COVID-19 swab (day 0). Slight leukopenia without neutropenia was observed on day 1. On day 7, neutropenia was observed with an absolute neutrophil count (ANC) of 1100. We decided to suspend clozapine and to initiate daily hematological controls. The ANC on day 8 was 970. Over the next few days the ANC will progressively improve until neutropenia resolved (day 22). 2- 55-year-old woman who required a transfer to a general hospital because of respiratory complications from COVID-19. She presented significant leukopenia (1’01x 10^3/uL) and neutropenia (ANC 100). Clozapine was not withdrawn. She was treated with granulocyte colony-stimulating factor.ConclusionsAn urgent full blood count will be required to exclude neutropenia with appropriate action. Further research will be needed to clarify the possible relationship between COVID-19, clozapine and neutropenia.DisclosureNo significant relationships.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.